Novan Welcomes Key Opinion Leaders to New Advisory Council
April 04, 2017 09:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., April 04, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company has formed an Advisory Council comprised of key opinion...
Novan Provides Update on SB204 Development Program
March 06, 2017 06:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., March 06, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that, after further analysis of the results from the NI-AC301 and NI-AC302...
Novan Announces SB204 Program Update Conference Call and Webcast
March 03, 2017 16:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., March 03, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company will host a conference call on Monday, Mar. 6, at 8 a.m....
Melinta Therapeutics Announces FDA Acceptance of Investigational New Drug Application for Topical Radezolid
February 28, 2017 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today the U.S. Food...
Dermira to Report Fourth Quarter and Full Year 2016 Financial Results
February 22, 2017 16:36 ET
|
Dermira, Inc.
MENLO PARK, Calif., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Novan Licenses SB204 to Sato for Acne in Japan
January 17, 2017 09:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., Jan. 17, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company has entered into an exclusive license agreement with Sato...
Novan to Present Data from SB204 Phase 2b Trial at Fall Clinical Dermatology Conference
October 18, 2016 09:05 ET
|
Novan, Inc.
DURHAM, N.C., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that results from the Company’s Phase 2b clinical trial to evaluate the efficacy...
Dermira Announces Proposed Public Offering of Common Stock
June 07, 2016 16:06 ET
|
Dermira, Inc.
MENLO PARK, Calif., June 07, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira to Present Preclinical Data from DRM01 Acne Program at the Society for Investigative Dermatology 75th Annual Meeting
May 11, 2016 16:05 ET
|
Dermira, Inc.
MENLO PARK, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira Reports First Quarter 2016 Financial Results and Provides Corporate Update
May 10, 2016 06:30 ET
|
Dermira, Inc.
- Positive Topline Results for DRM01 Phase 2b Acne Trial Reported; Phase 3 Program Planning Underway - Announcement of Topline Results for DRM04 Phase 3 Hyperhidrosis Pivotal Trials Expected in...